ICON PLC

ICON plc announced it will release its second quarter 2026 financial results after the market closes on Wednesday, July 29, 2026. The company will host a conference call and webcast to discuss these results and performance on Thursday, July 30, 2026, at 8:00am ET. Details for accessing the live webcast and replay will be available on the company's investor relations website.

ICON plc announced its Annual General Meeting (AGM) to be held on July 31, 2026, where shareholders will vote on the election or re-election of 10 directors, approval of 2025 accounts, auditor remuneration, and various share issuance and buyback authorities. The company also disclosed a restatement of its 2024 financial results following an investigation into accounting practices, which found improper adjustments to clinical trial services revenue. This resulted in a 1.1% decrease in 2024 revenue to $8.189 billion and a 6.7% decrease in profit to $727.077 million, with basic EPS restated to $8.81.

ICON PLC announced the divestment of Symphony Health Solutions Corporation, which merged with HealthVerity, resulting in ICON holding a minority equity interest in HealthVerity. The company also secured a $500 million Bridge Secured Credit Facility to refinance its 2026 Senior Secured Notes. For the first quarter of 2026, revenue slightly increased to $2.03 billion, but net income decreased to $104.75 million, and diluted earnings per share fell to $1.36. The company also received waivers for the late delivery of its 2025 annual and Q1 2026 financial statements.

ICON plc reported first-quarter 2026 results with revenue up 0.9% to $2,034.0 million, while GAAP diluted EPS decreased to $1.36 and adjusted diluted EPS fell to $2.50 compared to Q1 2025. The company demonstrated strong commercial momentum with net business wins of $2,880 million, a net book-to-bill of 1.42, and a 4.0% increase in backlog to $22.7 billion. ICON reaffirmed its full-year 2026 financial guidance for both revenue and adjusted diluted earnings per share.

ICON plc announced it will release its first quarter 2026 financial results after market close on Tuesday, June 23, 2026. Following the release, the company will host a conference call and webcast to discuss its financial performance on Wednesday, June 24, 2026, at 8:00 am ET. Details for accessing the webcast replay will be available on the company's investor relations website.

ICON plc reported its fourth quarter and full year 2025 financial results, alongside the conclusion of an Audit Committee investigation into accounting practices. The investigation found that revenue was overstated by 0.8% in 2023 and 1.1% in 2024, leading to a restatement of financials and identification of material weaknesses in internal controls. Despite this, the company reported strong Q4 net business wins and issued full-year 2026 financial guidance, while also announcing new board appointments.

ICON plc announced the restatement of its audited financial statements for the years ended December 31, 2024 and 2023, and unaudited interim financial statements for quarterly periods between March 31, 2023, and September 30, 2025. This action follows an Audit Committee investigation that identified improper adjustments to clinical trial services revenue and errors in cost estimation and realizable value. The restatement also includes significant additional goodwill and non-financial asset impairments, leading to a substantial negative adjustment to net income for the affected periods.

ICON plc announced it received a written notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Annual Report on Form 20-F for the year ended December 31, 2025. The notice has no immediate impact on the company's stock listing or trading, and Nasdaq has given ICON 60 days to submit a compliance plan. ICON expects to regain compliance by filing the Form 20-F, which it anticipates completing before its scheduled fourth quarter and full year 2025 earnings conference call on May 28, 2026.

ICON plc's Audit Committee has concluded that previously issued financial statements for 2023, 2024, and interim periods from Q1 2023 to Q3 2025 should no longer be relied upon. An investigation found revenue was overstated in 2023 and 2024, with a lesser impact in 2025. The company plans to restate these financials in its upcoming 2025 Annual Report on Form 20-F, which will also detail identified material weaknesses and remediation plans.